Valirx - Amends License for VAL201 with Cancer Research Technology
VAL Mon, 20 Dec 2021, 12:20pm GMT
ValiRx Plc is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering
Industry: Health Care
Dr Suzy Dilly, CEO of Valirx, discusses the amendment of the VAL201 license which will allow ValiRx and TheoremRx Inc. to proceed to full license without further CRT involvement.